A phase II randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in patients with cancer pain.

Narikazu Boku, Masaru Narabayashi, Shiro Fujita et al.|Journal of Clinical Oncology|2015

Cited by 1